The management of Candida infections in preterm neonates and the role of micafungin.

Paolo Manzoni, Daniel K. Benjamin, William Hope, Stefano Rizzollo, Paola Del Sordo, Mauro Stronati, Evelyne Jacqz-Aigrain, Elio Castagnola, Daniele Farina

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The burden of neonatal invasive Candida infection (ICI) has been increasing recently and identification of effective preventative and treatment strategies is a priority. In this view, the echinocandin class of antifungal agents has emerged as a suitable and promising option for treatment. These agents have overall characteristics that suitably meet the needs of neonatal patients, such as coverage against biofilms and against fluconazole-resistant strains of Candida spp, which is an issue in an epoch of increasing prophylactic use of fluconazole in the nursery. Micafungin is the only echinocandin authorized for neonatal use by the EMA, based on efficacy and PK data from neonatal populations. Although the kinetics and appropriate dosing of this agent in premature and term infants have been described in the recent years, through either neonatal studies or extrapolation form adult data, further studies are needed to better address this area. These studies should be properly designed for neonatal populations, and must better address long-term safety and the clinical outcomes related to echinocandin use in neonates.

Original languageEnglish
Pages (from-to)24-27
Number of pages4
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume24 Suppl 2
Publication statusPublished - Oct 2011

Fingerprint

Echinocandins
Candida
Fluconazole
Newborn Infant
Infection
Nurseries
Antifungal Agents
Biofilms
Premature Infants
Population
Safety
Therapeutics
micafungin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Manzoni, P., Benjamin, D. K., Hope, W., Rizzollo, S., Del Sordo, P., Stronati, M., ... Farina, D. (2011). The management of Candida infections in preterm neonates and the role of micafungin. Journal of Maternal-Fetal and Neonatal Medicine, 24 Suppl 2, 24-27.

The management of Candida infections in preterm neonates and the role of micafungin. / Manzoni, Paolo; Benjamin, Daniel K.; Hope, William; Rizzollo, Stefano; Del Sordo, Paola; Stronati, Mauro; Jacqz-Aigrain, Evelyne; Castagnola, Elio; Farina, Daniele.

In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 24 Suppl 2, 10.2011, p. 24-27.

Research output: Contribution to journalArticle

Manzoni, P, Benjamin, DK, Hope, W, Rizzollo, S, Del Sordo, P, Stronati, M, Jacqz-Aigrain, E, Castagnola, E & Farina, D 2011, 'The management of Candida infections in preterm neonates and the role of micafungin.', Journal of Maternal-Fetal and Neonatal Medicine, vol. 24 Suppl 2, pp. 24-27.
Manzoni, Paolo ; Benjamin, Daniel K. ; Hope, William ; Rizzollo, Stefano ; Del Sordo, Paola ; Stronati, Mauro ; Jacqz-Aigrain, Evelyne ; Castagnola, Elio ; Farina, Daniele. / The management of Candida infections in preterm neonates and the role of micafungin. In: Journal of Maternal-Fetal and Neonatal Medicine. 2011 ; Vol. 24 Suppl 2. pp. 24-27.
@article{cbcad09470324861901fe8f0c56e3c10,
title = "The management of Candida infections in preterm neonates and the role of micafungin.",
abstract = "The burden of neonatal invasive Candida infection (ICI) has been increasing recently and identification of effective preventative and treatment strategies is a priority. In this view, the echinocandin class of antifungal agents has emerged as a suitable and promising option for treatment. These agents have overall characteristics that suitably meet the needs of neonatal patients, such as coverage against biofilms and against fluconazole-resistant strains of Candida spp, which is an issue in an epoch of increasing prophylactic use of fluconazole in the nursery. Micafungin is the only echinocandin authorized for neonatal use by the EMA, based on efficacy and PK data from neonatal populations. Although the kinetics and appropriate dosing of this agent in premature and term infants have been described in the recent years, through either neonatal studies or extrapolation form adult data, further studies are needed to better address this area. These studies should be properly designed for neonatal populations, and must better address long-term safety and the clinical outcomes related to echinocandin use in neonates.",
author = "Paolo Manzoni and Benjamin, {Daniel K.} and William Hope and Stefano Rizzollo and {Del Sordo}, Paola and Mauro Stronati and Evelyne Jacqz-Aigrain and Elio Castagnola and Daniele Farina",
year = "2011",
month = "10",
language = "English",
volume = "24 Suppl 2",
pages = "24--27",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - The management of Candida infections in preterm neonates and the role of micafungin.

AU - Manzoni, Paolo

AU - Benjamin, Daniel K.

AU - Hope, William

AU - Rizzollo, Stefano

AU - Del Sordo, Paola

AU - Stronati, Mauro

AU - Jacqz-Aigrain, Evelyne

AU - Castagnola, Elio

AU - Farina, Daniele

PY - 2011/10

Y1 - 2011/10

N2 - The burden of neonatal invasive Candida infection (ICI) has been increasing recently and identification of effective preventative and treatment strategies is a priority. In this view, the echinocandin class of antifungal agents has emerged as a suitable and promising option for treatment. These agents have overall characteristics that suitably meet the needs of neonatal patients, such as coverage against biofilms and against fluconazole-resistant strains of Candida spp, which is an issue in an epoch of increasing prophylactic use of fluconazole in the nursery. Micafungin is the only echinocandin authorized for neonatal use by the EMA, based on efficacy and PK data from neonatal populations. Although the kinetics and appropriate dosing of this agent in premature and term infants have been described in the recent years, through either neonatal studies or extrapolation form adult data, further studies are needed to better address this area. These studies should be properly designed for neonatal populations, and must better address long-term safety and the clinical outcomes related to echinocandin use in neonates.

AB - The burden of neonatal invasive Candida infection (ICI) has been increasing recently and identification of effective preventative and treatment strategies is a priority. In this view, the echinocandin class of antifungal agents has emerged as a suitable and promising option for treatment. These agents have overall characteristics that suitably meet the needs of neonatal patients, such as coverage against biofilms and against fluconazole-resistant strains of Candida spp, which is an issue in an epoch of increasing prophylactic use of fluconazole in the nursery. Micafungin is the only echinocandin authorized for neonatal use by the EMA, based on efficacy and PK data from neonatal populations. Although the kinetics and appropriate dosing of this agent in premature and term infants have been described in the recent years, through either neonatal studies or extrapolation form adult data, further studies are needed to better address this area. These studies should be properly designed for neonatal populations, and must better address long-term safety and the clinical outcomes related to echinocandin use in neonates.

UR - http://www.scopus.com/inward/record.url?scp=84857090973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857090973&partnerID=8YFLogxK

M3 - Article

C2 - 21749182

AN - SCOPUS:84857090973

VL - 24 Suppl 2

SP - 24

EP - 27

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

ER -